Elvitegravir: A once-daily inhibitor of HIV-1 integrase

Expert Opinion on Investigational Drugs

Volumn 21, Issue 3, 2012, Pages 395-401

  Wills, Todd ^a   Vega, Vivian ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Antiretroviral therapy; Elvitegravir; HIV; Integrase inhibitor

Indexed keywords

ABACAVIR; COBICISTAT; CYTOCHROME P450 3A; DIDANOSINE; DOLUTEGRAVIR; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE; ETRAVIRINE; INTEGRASE; RALTEGRAVIR; RITONAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ANXIETY; ATTENTION DISTURBANCE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG HALF LIFE; DRUG METABOLISM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LETHARGY; MEDLINE; MOOD CHANGE; NIGHTMARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SYSTEMATIC REVIEW; VIRUS REPLICATION;

ANTI-HIV AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; QUINOLONES;

EID: 84856904753     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.658914     Document Type: Review

References (27)

1. UNAIDS. AIDS Epidemic update. Available from: http://www.unaids.org/ documents/20101123-GlobalReport-Chap2-em.pdf
2. Serrao E, Odde S, Ramkumar K, et al. Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-I integrase inhibitors. Retrovirology 2009;6:25-39
3. Dayam R, Al-Mawsawi LQ, Neamati N. HIV-1 integrase inhibitors: an emerging clinical reality. Drugs R D 2007;8:155-68 (Pubitemid 46707839)
4. Grant P, Zolopa A. Integrase inhibitors: a clinical review of raltegravir and elvitegravir. J HIV Ther 2008;13:36-9
5. Katlama C, Murphy R. Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection. Ther Clin Risk Manag 2009;5:331-40
6. Blanco JL, Varghese V, Rhee SY, et al. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011;203:1204-14
7. Metifiot M, Vandegraaff N, Maddali K, et al. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS 2011;25:1175-8
8. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007;46:125-33 (Pubitemid 47482607)
9. Murray JM, Emery S, Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor Raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007;21:2315-21 (Pubitemid 350287458)
10. Klibanov OM. Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. Curr Opin Investig Drugs 2009;10:190-200
11. Ramanathan S, Mathias AA, German P, et al. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 2011;50:229-44
12. Shimura K, Kodama EN. Elvitegravir: a new HIV integrase inhibitor. Antivir Chem Chemother 2009;20:79-85
13. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006;43:1-5 (Pubitemid 44306480)
14. Ramanathan S, Shen G, Hinkle J, et al. Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir. J Acquir Immune Defic Syndr 2007;46:160-6 (Pubitemid 47485733)
15. Ramanathan S, Kakuda TN, Mack R, et al. Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine. Antivir Ther 2008;13:1011-17
16. Zolopa A, Berger D, Lampiris H, et al. Activity of Elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized controlled dose-ranging clinical trial. J Infect Dis 2010;201:814-22.
17. Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011;25:F7-12.
18. Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Inf Dis 2012;1:27-35
19. Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor Elvitegravir (JTK-303/GS-9137). J Virol 2008;82:764-74
20. Prada N, Markowitz M, Novel integrase inhibitors for HIV. Expert Opin Investig Drugs. 2010;19:1087-98
21. Savarino A, Pistello M, D D'Ostillo, et al. Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS. Retrovirology 2007;4:79
22. Hare S, Vos AM, Clayton RF, et al. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance PNAS. 2010;107:20057-62
23. Eron J, Kumar P, Kazzarin A, et al. DTG in Subjects with HIV exhibiting ral resistance: functional monotherapy results of VIKING study cohort II. 18th conference on retroviruses and opportunistic infections. Paper 151LB. Available from: http://www. retroconference.org/2011/Abstracts/42541.htm [Accessed 21 December 2011]
24. Hare S, Smith SJ, Metifiot M, et al. Structural and Functional Analyses of the second-generation integrase stand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol 2011;80:565-72
25. Hightower KE, Wang R, DeAnda F, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011;55:4552-9
26. Panel on antiretroviral guidelines for adults and adolescents. guidelines for the use of antiretroviral agents in hiv-1-infected adults and adolescents. Department of health and human services. October 14, 2011; 1-166. Available from: http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL. pdf [Accessed 4 November 2011]
27. Molina JM, Cahn P, Grinsztein B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind activecontrolled trial. Lancet 2011;378:238-46